Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-005580-32-AT

Enrollment

Registered

2021-04-15

Start date

2021-04-26

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antiviral effect of silibinin against SARS-CoV2

Interventions

Trade Name: Legalon SIL Product Name: Legalon SIL Pharmaceutical Form: Lyophilisate for solution for infusion INN or Proposed INN: Silibinin-C-2’, 3-bis (hydrogensuccinat) Other descriptive name: Sili

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mild COVID-19 disease without the need for assisted ventilation Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria: Need for assisted ventilation

Design outcomes

Primary

Measure	Time frame
Main Objective: antiviral treatment of mild COVID-19 disease with silibinin by examining viral elimination kinetics;Secondary Objective: Not applicable;Primary end point(s): Viral decay on day 10 or undetectable virus by PCR at any time before day 10;Timepoint(s) of evaluation of this end point: day10	—

Secondary

Measure	Time frame
Secondary end point(s): day10;Timepoint(s) of evaluation of this end point: day 10	—

Countries

Austria

Contacts

Public ContactPeter Ferenci

Medical University of Vienna

peter.ferenci@meduniwien.ac.at0043140400 47440

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026